Background {#psp412390-sec-0001}
==========

Reproducibility lies at the heart of scientific research. Yet a recent survey found that 70% of scientists have tried and failed to reproduce results from a published experiment.[1](#psp412390-bib-0001){ref-type="ref"} This is a critical problem for the pharmaceutical industry, where multimillion‐dollar drug development programs emanate from discoveries in academic laboratories. Scientists at Bayer have reported that only \~25% of published preclinical studies could be validated to the point at which projects could progress.[2](#psp412390-bib-0002){ref-type="ref"} Depressingly, Amgen scientists reported that only 6/53 (11%) "landmark" cancer studies could be reproduced in‐house.[3](#psp412390-bib-0003){ref-type="ref"} Although the specific publications were not disclosed, these same targets were likely pursued to no avail by many other academic and industrial groups.

One would presume that simulated results emanating from computational experiments would fare better. Anyone who has tried to recreate a model and replicate a simulation from an article may not be so sure. Indeed, the reproducibility of published computational research has been reported as similarly dismal (\~25%).[4](#psp412390-bib-0004){ref-type="ref"} The barriers to computational reproducibility include a lack of standardization for building and representing models, a lack of documentation on usage, and a lack of transparency (sometimes intentional) by authors[5](#psp412390-bib-0005){ref-type="ref"} in addition to simple coding errors and typos.

Computational modeling and simulation is playing an increasingly critical role in drug research, development, and regulatory decision making. The US Food and Drug Administration has recently launched a number of initiatives to advance model‐informed drug development, outlined in the The Prescription Drug User Fee Act (PDUFA) VI.[6](#psp412390-bib-0006){ref-type="ref"} To fulfill this role, model reproducibility and methodological transparency are imperative. Clinical pharmacometrics (pharmacokinetic and exposure--response models) have largely achieved this out of necessity. Pharmacokinetic/pharmacodynamic model simulations are typically included in regulatory submissions, and reviewers will often attempt to independently replicate these results. Standardized software packages (i.e., NONMEM), annotation rules, and file formats smooth the process. Transparency and consistency can be worth millions if they mean expediting a drug approval.

Pharmacometrics as a discipline has, however, taken more than 40 years of evolution to reach this state. Quantitative systems pharmacology (QSP) lacks this degree of standardization as a result of both the newness of the discipline and fundamental differences from pharmacometrics the use of a wide diversity of data types, model formalisms, biological scales, and objectives beyond dose projection.[7](#psp412390-bib-0007){ref-type="ref"} Still, QSP results should be reproducible in that individuals should be able to replicate simulations from an article without contacting the authors. This is important if models are to be reused for new data or repurposed to new projects, as a lack of reproducibility hinders good models from "bubbling up" in the literature. The ease of reproducibility is also critical if QSP is to play a greater role in drug development and regulatory decisions.[8](#psp412390-bib-0008){ref-type="ref"}

In "Ten Simple Rules for Reproducible Computational Research," the last, but not least, important rule states that all data and model code should be publicly available and easily accessible.[9](#psp412390-bib-0009){ref-type="ref"} *CPT: Pharmacometrics & Systems Pharmacology* has a crucial role to play here. The provision of model code is required for publication, and as an open access journal, this ensures model availability. However, as files are buried in supplementary materials with no unique identifiers, structure, or standardized annotation, model accessibility remains a problem.

To help alleviate this problem, we set forth to establish a searchable repository of QSP models published in *CPT: Pharmacometrics & Systems Pharmacology*. Although QSP research is published in numerous journals (e.g., *Journal of Pharmacokinetics and Pharmacodynamics*,*npj Systems Biology and Applications,* and basic science and engineering journals), we limited the scope to assess feasibility of this American Society of Clinical Pharmacology and Therapeutics--directed project. We next describe the challenges faced in our (failed) attempt to achieve this goal.

Literature Search {#psp412390-sec-0002}
=================

A PubMed literature search was conducted (October 2018) to identify relevant publications and embedded models for inclusion in the repository. To do so, we queried PubMed with the following search terms:""CPT: pharmacometrics & systems pharmacology"\[Journal\] AND ("Systems" \[Title\] OR "QSP" \[Title\]) AND Model\* \[Title\]."

The search resulted in 43 publications. These publications were manually curated by reading abstracts to include only primary QSP research articles (i.e., excluding reviews and commentaries, model analyses, and methodology‐focused publications) that included intact model code in their [supplemental information](#psp412390-sup-0003){ref-type="supplementary-material"}, resulting in a total of 18 (**Table ** [1](#psp412390-tbl-0001){ref-type="table"}). The supplementary material packages were downloaded from each publication. An additional nine were found to include only pseudo‐code or references to other publications and were thus not considered further (**Supplement ** [**1**](#psp412390-sup-0002){ref-type="supplementary-material"}). As a caveat, this excludes many relevant publications that do not include "systems" or "QSP" in their title[10](#psp412390-bib-0010){ref-type="ref"}, [11](#psp412390-bib-0011){ref-type="ref"} and highly impactful models published elsewhere.[12](#psp412390-bib-0012){ref-type="ref"} Although a more thorough analysis of the published literature would be valuable, this would require text‐mining methods, which is beyond the scope of this initial feasibility project. The results from our analyses of this limited set of models is nonetheless revealing.

###### 

Summary of 18 QSP models

  PMID       Title                                                                                                                                                                                                 Author, year        Language                Executable
  ---------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- ----------------------- ------------
  29637732   Quantitative Systems Pharmacology Model of hUGT1A1‐modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler‐Najjar Syndrome Type 1                                                                      Apgar (2018)        KroneckerBio (MATLAB)   No
  28548387   A Quantitative Systems Physiology Model of Renal Function and Blood Pressure Regulation: Model Description                                                                                            Hallow (2017)       R                       Error
  26312163   Using a Systems Pharmacology Model of the Blood Coagulation Network to Predict the Effects of Various Therapies on Biomarkers                                                                         Nayak (2015)        SimBiology (MATLAB)     No
  26225228   A Systems Pharmacology Model of Erythropoiesis in Mice Induced by Small Molecule Inhibitor of Prolyl Hydroxylase Enzymes                                                                              Singh (2015)        Fortran                 Not tested
  28188981   A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations                                                             Gadkar (2014)       SimBiology (MATLAB)     Yes
  24918743   Effects of IL‐1β--Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms                                              Palmér (2014)       Mathematica             Not tested
  23903463   Quantitative Systems Pharmacology Model of NO Metabolome and Methemoglobin Following Long‐Term Infusion of Sodium Nitrite in Humans                                                                   Vega‐Villa (2013)   NONMEM                  Not tested
  28941225   Systems Pharmacology Model of Gastrointestinal Damage Predicts Species Differences and Optimizes Clinical Dosing Schedules                                                                            Shankaran (2017)    MATLAB                  Error
  28571112   A Translational Systems Pharmacology Model for Aβ Kinetics in Mouse, Monkey, and Human                                                                                                                Karelina (2017)     DBSolve                 Not tested
  27537780   A Systems Model for Ursodeoxycholic Acid Metabolism in Healthy and Patients With Primary Biliary Cirrhosis                                                                                            Zuo (2016)          MATLAB                  No
  27299938   Systems Pharmacology Modeling of Prostate‐Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down‐Regulator                                           Mistry (2016)       MATLAB                  No
  26783501   A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics                                                  Zhou (2015)         SimBiology (MATLAB)     No
  26451331   Application of a Systems Pharmacology‐Based Placebo Population Model to Analyze Long‐Term Data of Postmenopausal Osteoporosis                                                                         Berkhout (2015)     NONMEM                  Not tested
  24402117   Scale Reduction of a Systems Coagulation Model With an Application to Modeling Pharmacokinetic--Pharmacodynamic Data                                                                                  Gulati (2014)       MATLAB                  No
  23887363   Integrated Pharmacometrics and Systems Pharmacology Model‐Based Analyses to Guide GnRH Receptor Modulator Development for Management of Endometriosis                                                 Riggs (2012)        Berkeley Madonna        Not tested
  30270578   A Quantitative Systems Pharmacology Kidney Model of Diabetes Associated Renal Hyperfiltration and the Effects of SGLT Inhibitors                                                                      Balazki (2018)      PK‐Sim/MoBi             Yes
  30043496   Automated Scale Reduction of Nonlinear QSP Models With an Illustrative Application to a Bone Biology System                                                                                           Hasegawa (2018)     MATLAB                  Yes
  29920993   Quantitative Systems Pharmacology Modeling of Acid Sphingomyelinase Deficiency and the Enzyme Replacement Therapy Olipudase Alfa Is an Innovative Tool for Linking Pathophysiology and Pharmacology   Kaddi (2018)        MATLAB                  Yes

QSP, quantitative systems pharmacology.

John Wiley & Sons, Ltd

Model Analyses {#psp412390-sec-0003}
==============

Software diversity {#psp412390-sec-0004}
------------------

The most striking although perhaps unsurprising finding was the diversity of software platforms employed (**Figure ** [**1**](#psp412390-fig-0001){ref-type="fig"}). Although MATLAB (MathWorks, Natick, MA) and its dependents (SimBiology and KroneckerBio) predominated, NONMEM (ICON, Dublin, Ireland), R, PK‐Sim/MoBi (Bayer, Leverkusen, Germany), Mathematica (Wolfram Research, Champaign, IL, USA), DBSolve (InSysBio, Moskow, Russia), Berkeley Madonna (University of California, Berkeley, CA), and Fortran (IBM, Armonk, NY) were also represented. The file formats supplied in the supplements were also diverse, spanning .doc, .txt, .xlsx, .pdf, and .m files as well as the number of files per model from a single script to 23 individual files. Model annotation also varied extensively, from a single "run" script, which would automatically generate figures, to a set of ordinary differential equations (ODEs) requiring time, initial conditions, and parameter vectors as inputs to run.

![Workflow and results summary. QSP, quantitative systems pharmacology.](PSP4-8-205-g001){#psp412390-fig-0001}

Model reproducibility {#psp412390-sec-0005}
---------------------

Lacking the technical proficiency or software to assess all 18 models, we settled on testing the subset written in R (1), PK‐Sim/MoBi (1), or MATLAB and its dependents (10). By "testing," we evaluated how many cases contained scripts that would generate a simulation without extensive coding, i.e., executable.

Of the 10 MATLAB‐based models, the packages provided by Hasegawa and Duffull*,* [13](#psp412390-bib-0013){ref-type="ref"} Kadidi *et al*.[14](#psp412390-bib-0014){ref-type="ref"} and Gadkar *et al*.[15](#psp412390-bib-0015){ref-type="ref"} all contained "readme" text files describing the code and a single "run" script that loaded multiple files, executed simulations, and generated pharmacokinetic/pharmacodynamic time course figures from the associated manuscripts (**Figures ** [**S1--S3**](#psp412390-sup-0001){ref-type="supplementary-material"}). The model of chemotherapy‐induced gastrointestinal damage by Shankaran *et al*.[16](#psp412390-bib-0016){ref-type="ref"} purported such in the code annotation, but the supplement did not contain a critical Excel file required to execute the simulation. The model of diabetes‐associated renal hyperfiltration by Balazki *et al.,* [17](#psp412390-bib-0017){ref-type="ref"} coded in PK‐Sim/MoBi, also contained both the MOBI model files as well as R‐based "run" scripts that generated figures from the manuscript (**Figure ** [**S4**](#psp412390-sup-0001){ref-type="supplementary-material"}). A model of renal physiology and control mechanisms developed by Hallow and Gebremichael[18](#psp412390-bib-0018){ref-type="ref"} contained well‐annotated R code and accompanying run scripts. However, we were unable to execute because of issues associated with the parameter file. In none of the other models tested were we able to generate a simulation using a similar run file. Thus, 4/12 models tested were deemed functionally executable. Note that nonexecutable does not mean that the code is erroneous or nonfunctional, nor say anything about the quality of the work, but only that it would take significant efforts to replicate a simulation from the associated manuscript using the files provided. Many models contained only the "base" model, i.e., the set of equations, with parameters often saved in a separate file, such that one would need to write custom code to load the model and execute simulations. This would rely on the text describing these simulations in sufficient detail to be able to reproduce the calculations.

Best Practice Recommendations for Publishing QSP Models {#psp412390-sec-0006}
=======================================================

It would be both challenging and perhaps of little use to create a searchable database from such a jumble of files. We have provided the materials in a single folder for readers to access and assess for themselves (**Supplement ** [**2**](#psp412390-sup-0003){ref-type="supplementary-material"}). As QSP models are coded in many different software platforms by practitioners from diverse backgrounds, there is no consistency in how models are annotated or executed, nor should there be at this stage. We seek here not to provide firm rules as to how model code should be provided but, rather, to start a discussion as to what can be done to make QSP model reproducbility and sharing easier than it exists today. The following sections provide some ideas.

Near term {#psp412390-sec-0007}
---------

The most immediately practical idea is the provision of a single "run" script that loads and simulates the model (perhaps calling multiple provided files) to generate at least one figure from the publication and an associated "readme" file that succinctly describes such. In our experience, the extra effort required to do so can save time and headache in the long run, minimizing email exchanges regarding questions about how to use the provided code.

Guidelines should be provided by journals as to how model code should be submitted and made accessible, rather than simply request one to "provide model code." Although we do not intend to establish what this would be, annotation standards could start with those described in the minimum information requested in the annotation of biochemical models.[19](#psp412390-bib-0019){ref-type="ref"} Checklists are typically required for the description of experimental data and methods,[20](#psp412390-bib-0020){ref-type="ref"} and similar checklists could be created toward model code. *Nature* has in fact recently released guidelines for code and software submission.[21](#psp412390-bib-0021){ref-type="ref"}

In addition to model annotation, sufficient details should be provided to describe individual simulations and analyses. Some existing tools provide this as part of their project files, for example, MATLAB SimBiology models are encoded as a single *sbproj* file, which can include experimental conditions (e.g., dosing protocols), and these can be exported to (open‐source) systems biology markup language (SBML). We are aware of at least one case of successful model sharing using such details. An SBML file and a single MATLAB "run" script[22](#psp412390-bib-0022){ref-type="ref"} was translated into R via the *mgrsolve* package and then used to create a R‐Shiny application without any input from the authors, with the entire process taking only of a few hours of work.[23](#psp412390-bib-0023){ref-type="ref"}

Longer term {#psp412390-sec-0008}
-----------

Authors could potentially be rewarded with a "badge" for articles that meet some threshold of model reproducibility during peer review. This would incentivize the provision of functional, well‐annotated code and "run" scripts.

This would of course place the burden of functional code on reviewers, who may lack the software or technical proficiency to do so in all cases. Alternatively, journals could establish an annually elected small group of professionals, postdocs, and/or doctorate candidates capable and willing to provide model evaluation tests. Similar to the model qualification procedure developed within the DDMoRe Consortium,[24](#psp412390-bib-0024){ref-type="ref"} this review group could ensure code functionality while granting young professionals valuable experience and insight into the review process. However, getting such a system established and integrated smoothly into the review process would be a significant undertaking.

As is the case for genomics data sets, journals could request authors to provide models in an established repository. Two such model repositories currently exist: BioModels[25](#psp412390-bib-0025){ref-type="ref"} geared toward cell‐ and molecular‐based systems models and DDMoRE[26](#psp412390-bib-0026){ref-type="ref"} for pharmacometrics. Consortiums have also been established to develop more comprehensive tissue‐ and disease‐focused models, such as DILIsym[27](#psp412390-bib-0027){ref-type="ref"} (drug‐induced liver injury), Certara\'s QSP Immunogenicity Consortium, or the Critical Path for Alzheimer\'s Disease; hence, these may serve in specific cases.

QSP models should ultimately be provided in an open‐source, standardized format. Although no single standard currently exists, there are a number of options, such as SBML,[28](#psp412390-bib-0028){ref-type="ref"} PharmML,[29](#psp412390-bib-0029){ref-type="ref"} and PK‐Sim/MoBi.[30](#psp412390-bib-0030){ref-type="ref"} However, given the extra effort required to do so and the fact that QSP work is rarely scripted in such platforms, such a requirement may simply impede publication rather than enhance sharing at this point. As an alternate "standard" format, an Excel or text file listing the full set of reactions, associated rate laws, and parameters could suffice. Such files can be converted into equations and executable code with relative ease by many software platforms.

A fundamental challenge with all the above is that results often require substantial computation on clusters or clouds and may depend on multiple software packages and data sets to generate. Furthermore, the results may depend on libraries for which the authors do not have permission to redistribute or complex chains of open‐source software configured in a particular way. Reproducibility in such cases is not simply a matter of providing access to the model and executable code but access to the computational environment used to generate the results.

Here we may look to the software industry for a potential solution, where the software‐as‐a‐service model has addressed this issue by bundling together software, data, and computation into a single offering. Particularly for cases for which a single "run" script does not suffice, authors could provide access not only to the model and code but also to the underling technical infrastructure. This removes the burden on the individual scientist to download software and replicate the computing environment. Consistent with this, *Nature* has recently launched a test trial with Code Ocean, a cloud‐based computing platform that enabes authors to share fully functional and executable code.[31](#psp412390-bib-0031){ref-type="ref"} Obviously, this raises new issues around how long such services would need to be maintained and who would bear that expense.

Given the diversity of opinions on how best to meet these challenges, workshops should be organized, perhaps through the American Society of Clinical Pharmacology and Therapeutics or the International Society of Pharmacometrics, to discuss practical strategies to move forward.

Going Forward {#psp412390-sec-0009}
=============

What should model sharing look like? Is providing the set of equations and parameters underlying a model sufficient? As with experimental protocols, the procedures involved in executing a simulation often contain many details and nuances not captured in a set of equations. At the other extreme, should one be able to generate every figure in an article from a single script? This is the bar set by bioinformatics,[32](#psp412390-bib-0032){ref-type="ref"} although probably an unreasonable expectation for QSP. Such a requirement may simply dissuade publishing, particularly for industry scientists who must balance the desire to publish with project timelines and the need to guard proprietary information. Given the diversity of QSP, it is unclear to what end of the spectrum should be required or is reasonable to request. The provision of a single "run" script, when feasible, is the most immediately tractable idea. Continued dialogue within the community via publications, workshops, or other meeting forums will be necessary to reach some consensus.

Many have had the experience of attempting to extract a model from an article and reproduce a result only to be met with errors and frustration, necessitating a back and forth with the authors, sometimes with success and sometimes to no avail. If we can find ways to lesson this hardship, the field will be better for it.
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###### 

**Figure S1.** Pharmacokinetic/pharmacodynamic plots generated from Hasegawa *et al*. model.

**Figure S2.** Pharmacokinetic/pharmacodynamic plots generated from Kadidi *et al*.[14](#psp412390-bib-0014){ref-type="ref"} model.

**Figure S3.** Pharmacokinetic/pharmacodynamic plots generated from Gadkar *et al*. model.

**Figure S4.** Pharmacokinetic/pharmacodynamic plots generated from Balazki *et al*. model.
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**Supplementary Material S1.** Results of Pubmed query.
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**Supplementary Material S2.** Model files provided in supplementary materials of 18 publications.
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